This content is machine translated Oral JAK-i in atopic dermatitis Benefits and risks: What does the current data say? Although there have been no recent approvals of oral JAK inhibitors (JAK-i) for atopic dermatitis (AD), some interesting study findings have been published. These shed light on the safety of...…
View Post 6 min This content is machine translated Atopic dermatitis Biologics and JAK-i – the best of both worlds In Switzerland, both the currently approved monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and the Janus kinase (JAK) inhibitors (baricitinib, abro-citinib, upadacitinib) can be used as “first-line” systemic therapy for patients with...…
View Post 3 min This content is machine translated Tofacitinib for ulcerative colitis Study shows real-world evidence for efficacy and safety The prevalence of ulcerative colitis (CU) in Switzerland is 1/500. The JAK inhibitor tofacitinib has been an arrow in the treatment quiver since 2019. In the phase 3 OCTAVE study,…
View Post 10 min This content is machine translated Hand eczema: Guideline 2023 Therapy depends on the severity The new edition of the guideline “Diagnosis, prevention and treatment of hand eczema”, which was published this year under the auspices of the German Dermatological Society, focuses in particular on…
View Post 6 min This content is machine translated Chronic itching Non-trivial – despite proven and new system therapies Chronic pruritus can occur at any age and affect different groups of patients. A guideline-based approach is advisable in order to determine the cause and provide the best possible treatment…
View Post 5 min This content is machine translated Update EULAR treatment recommendations Carefully consider the use of JAK inhibitors The goal of rheumatoid arthritis (RA) therapy today is clinical remission. The earlier the disease is detected, the better the chances of achieving this goal. For the road ahead, EULAR…
This content is machine translated Rheumatoid arthritis in elderly patients Evidence-based therapy selection under the aspect of benefits and risks Current evidence suggests that the benefits of low-dose steroid therapy are greater than the harms in elderly patients with rheumatoid arthritis (RA). This is evident from the GLORIA study, in…
View Post 4 min This content is machine translated System therapy for atopic dermatitis: biologics or JAK inhibitors? Balancing benefits and risks The era of targeted systemic treatment began several years ago and the therapy armamentarium is constantly expanding, so that the question of selection criteria for the individually appropriate therapy is…
View Post 6 min This content is machine translated Atopic eczema EuroGuiDerm guideline – overview of current recommendations for system therapy Recently, there have been significant advances in the treatment of atopic dermatitis, including several new systemic therapeutic options overcoming regulatory hurdles. This has also been incorporated into the EuroGuiDerm guideline…
View Post 16 min This content is machine translated Moderate to severe atopic dermatitis Changing therapeutic landscape – broad arsenal of treatment options New therapies in the form of specific antibodies and “small molecules” have ushered in a new era. Biologics intervene in the inflammatory process of atopic dermatitis by targeting individual cytokines.… CME-Test
View Post 3 min This content is machine translated Atopic dermatitis: JAK inhibitors Baricitinib combined with topical steroids achieves high patient benefit When topical steroid therapy alone is not sufficiently effective, patients with atopic dermatitis may benefit greatly from the additional use of the JAK inhibitor baricitinib. This is shown, among other…
